Factors associated with the loss of response to infliximab in patients with Crohn's disease

► Infliximab (IFX) is effective for Crohn's disease treatment. However, antibodies to IFX emerge. ► We conducted the study for loss of response (LOR) to IFX and how LOR patients may be treated. ► Dose frequency was 8 weeks in responders and 4 weeks in LOR patients, but trough IFX was same. ► CDAI and CRP as well as sIL-2R, ANA and CIC were higher in LOR patients. ► Granulocyte/monocyte apheresis showed immunormodulatory effects for patients with LOR.